CINECA IRIS Institutional Research Information System

BARRESI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.923
EU - Europa 2.584
AS - Asia 956
AF - Africa 134
OC - Oceania 27
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.631
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.764
IT - Italia 1.274
CN - Cina 407
SE - Svezia 353
SG - Singapore 279
DE - Germania 253
BG - Bulgaria 179
AT - Austria 174
CA - Canada 155
GB - Regno Unito 80
VN - Vietnam 72
FR - Francia 67
JP - Giappone 56
RU - Federazione Russa 52
CI - Costa d'Avorio 51
IN - India 46
TR - Turchia 44
FI - Finlandia 39
NG - Nigeria 39
SN - Senegal 37
HK - Hong Kong 32
AU - Australia 27
BE - Belgio 27
UA - Ucraina 20
NL - Olanda 14
CZ - Repubblica Ceca 12
PL - Polonia 12
EG - Egitto 6
CH - Svizzera 5
KR - Corea 5
BR - Brasile 4
ES - Italia 4
HU - Ungheria 4
PK - Pakistan 4
RO - Romania 4
TW - Taiwan 3
DK - Danimarca 2
EE - Estonia 2
HR - Croazia 2
IR - Iran 2
MX - Messico 2
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
DZ - Algeria 1
EU - Europa 1
GR - Grecia 1
ID - Indonesia 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MC - Monaco 1
MD - Moldavia 1
PA - Panama 1
PT - Portogallo 1
Totale 7.631
Salva come PNG Salva come JPEG
Città #
Serra 560
Woodbridge 393
Fairfield 363
Ann Arbor 343
Chandler 332
Houston 302
Ashburn 269
Sofia 179
Seattle 168
Vienna 156
Ottawa 146
New York 144
Singapore 142
Wilmington 130
Beijing 118
Princeton 109
Boardman 106
Cambridge 105
Santa Clara 102
Frankfurt am Main 91
Lawrence 78
Milan 74
Medford 73
Des Moines 70
Pisa 54
Abidjan 51
Dearborn 47
Rho 41
Bremen 40
Lagos 39
Dakar 37
London 37
Nanjing 31
Hong Kong 28
Istanbul 28
Brussels 27
Florence 27
Dong Ket 25
Los Angeles 25
San Jose 24
Livorno 22
Sydney 22
Boulder 20
Pessac 19
Shanghai 19
Ogden 18
San Diego 18
Pune 16
Fuzhou 15
Izmir 15
Jacksonville 15
Cascina 14
Rome 14
Aversa 13
Pistoia 13
Redwood City 13
Vicopisano 13
Alessandria 12
Changsha 12
Hefei 12
Quanzhou 12
Shenyang 12
Kunming 11
Vercelli 11
Nanchang 10
Santa Margherita Ligure 10
Talence 10
Lancaster 9
Toronto 9
Warsaw 9
Council Bluffs 8
Helsinki 8
Jiaxing 8
Norwalk 8
Auburn Hills 7
Gif-sur-yvette 7
Hebei 7
Nürnberg 7
Tianjin 7
Arezzo 6
Brno 6
Citta 6
Hangzhou 6
Hyderabad 6
Kyoto 6
Paris 6
Phoenix 6
Tokyo 6
Xiamen 6
Falls Church 5
Garbagnate Milanese 5
Guangzhou 5
Lucca 5
Prague 5
Scafati 5
Amsterdam 4
Cairo 4
Castelnuovo di Garfagnana 4
Dortmund 4
Edinburgh 4
Totale 5.709
Salva come PNG Salva come JPEG
Nome #
TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance 257
Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma 220
Benzofuroxane Derivatives as Multi Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies 205
Allosteric modulators of human A2B adenosine receptor. 183
Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects 182
Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides 169
TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy 167
TSPO PIGA ligands promote neurosteroidogenesis and human astrocyte well-being 166
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities 166
Arylthioamides as H2S Donors:l-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo 155
Drug-target Residence Time: a key parameter in glial responses to TSPO ligands 152
Residence Time (RT), a new parameter to predict neurosteroidogenic efficacy of Translocator Protein (TSPO) ligands: N,N-dialkyl-2-arylindol-3-ylglyoxylamides, a case study 146
Modulation of A2B Adenosine Receptor by 1-Benzyl-3-ketoindole Derivatives 139
Targeting the 18-kDa translocator protein: Recent perspectives for neuroprotection 138
Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII 138
Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts 134
Modulation of A2B adenosine receptor by 1-benzyl-3-ketoindole derivatives 132
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of non-camptothecin Topoisomerase I (Top1) inhibitors 130
An update into the medicinal chemistry of translocator protein (TSPO) ligands 129
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A(2B) adenosine receptor antagonists 118
Translocator protein (tspo) ligand residence time: a new parameter to predict neurosteroidogenic efficacy for n,n-dialkyl-2-arylindol-3-ylglyoxylamides (PIGAs) 115
An irreversible ligand of the 18 kDa Translocator Protein induces rapidly ΔΨm collapse and activates apoptosis in human glioblastoma multiforme cells. 114
Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A1 and A2B adenosine receptor subtypes 113
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A Novel Template for the Design of Highly Selective A(2B) Adenosine Receptor Antagonists. 112
Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas 109
4-Substituted Benzenesulfonamides Incorporating Bi/Tricyclic Moieties Act as Potent and Isoform-Selective Carbonic Anhydrase II/IX Inhibitors 109
Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases 109
Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells 108
Novel positive allosteric modulators of A2B adenosine receptor acting as bone mineralisation promoters 107
Exploiting the 4-Phenylquinazoline Scaffold for the Development of High Affinity Fluorescent Probes for the Translocator Protein (TSPO) 103
Allosteric modulation of A2B adenosine receptors potentiate the effects of orthosteric receptor agonists to promote mesenchymal stem cell differentiation to osteoblasts. 101
Structure-Activity Relationship Refinement and Further Assessment of 4-Phenylquinazoline-2-carboxamide Translocator Protein Ligands as Antiproliferative Agents in Human Glioblastoma Tumors. 100
Two mixed valence diruthenium(ii,iii) isomeric complexes show different anticancer properties 100
Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3- d]pyrimidine-Based Antiproliferative Multikinase Inhibitors 98
De novo neurosteroidogenesis in human microglia: Involvement of the 18 kda translocator protein 95
Unbinding of Translocator Protein 18 kDa (TSPO) Ligands: From in Vitro Residence Time to in Vivo Efficacy via in Silico Simulations 88
Glioblastoma multiforme: induction of mitochondria-mediated apoptotic pathway by simultaneous pharmacological activation of TSPO (18KDa) and p53. 86
A mixed-valence diruthenium(ii,iii) complex endowed with high stability: from experimental evidence to theoretical interpretation 86
Carbonic anhydrase activation profile of indole-based derivatives 83
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of noncamptothecin Topoisomerase I (top1) inhibitors 80
Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A3 adenosine receptor 80
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors 80
2-(phenylsulphonamido)-pyrazole derivatives as carbonic anhydrase inhibitors 79
Refinement of the Mitochondrial Translocator Protein Pharmacophore/Receptor Model via Structure-activity Relationships of Novel N,N-Dialkylindolylglyoxylamides 78
Benzoxadiazole Derivatives: Atypical Inhibitors of Aldose Reductase 76
Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications 76
Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies 75
Interaction of the irreversible ligand IRDE-MPIGA with TSPO (18 KDa): new insight on TSPO role in tumor cells. 73
Refinement of the translocator protein pharmacophore/receptor model via structure-activity relationships of novel N,N-dialkylindolylglyoxylamides 71
Inhibition studies on carbonic anhydrase isoforms I, II, IV and IX with N-arylsubstituted secondary sulfonamides featuring a bicyclic tetrahydroindazole scaffold 71
Design and synthesis of novel indolylglyoxylamide derivatives as molecular probes for 18 KDa translocator protein (TSPO) 70
3-Aryl-1,2,4-triazino-4,3-abenzimidazol-4(10H)-one: a novel template for the design of highly selective A2B adenosine receptor antagonists 69
Iminothioethers As A Novel Class Of H2s-Donor: Gasotransmitter Release And Vascular Effects 68
Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs 68
Iminothioethers as a novel class of H2S-donor: gasotransmitter release and vascular effects 67
null 63
Development of a New A2B Adenosine Receptors PET ligand: 3- Phenyl-1-[11C]methyl-3- aryl[1,2,4]triazino[4,3 -a]benzimidazol-4(10H)-one 60
N,N-dialkyl-5-isothiocyanato-2-phenylindol-3-ylglyoxylamide: an irreversible ligand to study the translocator protein 59
Strategies for the improvement of metal-based chemotherapeutic treatments 57
Carbonic Anhydrase Activators for Neurodegeneration: An Overview 56
New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: synthesis and pharmacological effects 55
Refinement of the Mitochondrial Translocator Protein Pharmacophore/Receptor Model via Structure-activity Relationships of Novel N,N-Dialkylindolylglyoxylamides 54
Lead optimization of a novel molecular scaffold in search for novel MMP-13 inhibitors 52
Indole-based modulators of p53/MDM2 interaction as antitumoral agents 51
Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging 51
Development of novel indole-based tdp1 inhibitors for anticancer therapy 50
New suitable scaffolds for the development of non camptothecin topoisomerase I (Top1) inhibitors 50
Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies 50
Labeling of TSPO PET radioligands by [18F]fluorination of diarylsulfoxide precursors 47
Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders 47
Translocator Protein 18-kDa: a promising target to treat neuroinflammation-related degenerative diseases 47
Targeting TSPO Reduces Inflammation and Apoptosis in an In Vitro Photoreceptor-Like Model of Retinal Degeneration 45
Modulation of PAR1 signaling by benzimidazole compounds 45
Refinement of the Mitochondrial Translocator Protein Pharmacophore/Receptor Model via Structure-activity Relationships of Novel N,N-Dialkylindolylglyoxylamides. 44
N,N-dialkyl-5-isothiocyanato-2-phenylindol-3-ylglyoxylamide: an irreversible ligand to study the translocator protein 42
Radiosynthesis of the TSPO 18 kDa PET Radiotracer [18F](R)-PK14105 42
A complex bearing TSPO PIGA ligand coordinated to the [Au(PEt3)]+ pharmacophore is highly cytotoxic against ovarian cancer cells 39
A cyanine-based NIR fluorescent Vemurafenib analog to probe BRAFV600E in cancer cells 38
H2S-releasing properties of new thioamide derivatives 37
Indole-based modulators of p53/MDM2 interaction as antitumoral agents 35
Drug repurposing meets DNA independent pathways: targeting alternative substrates for anticancer therapy 34
Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021) 34
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents 31
Allosteric Modulators of Adenosine Receptors 26
Indol-3-ylglyoxylamide as Privileged Scaffold in Medicinal Chemistry 26
Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapy-An Overview 25
Toward PET imaging of A2B adenosine receptors: A carbon-11 labeled triazinobenzimidazole tracer. Synthesis and imaging of a new A2B PET tracer 24
Enriching the arsenal of pharmacological tools against mical2 24
Metformin conjugates and therapeutic use thereof 23
Diruthenium(ii,iii) paddlewheel complexes: effects of bridging and axial ligands on anticancer properties 22
null 20
Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents 20
Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate H2S Donor Moiety, in Different Cancer Cell Lines 20
Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth - An Investigation of the Activation Mechanism and Their Nanoformulation 16
TSPO Radioligands for Neuroinflammation: An Overview 10
Targeting the Translocator Protein (18 kDa) in Cardiac Diseases: State of the Art and Future Opportunities 8
Pursuing Polypharmacology: Benzothiopyranoindoles as G-Quadruplex Stabilizers and Topoisomerase I Inhibitors for Effective Anticancer Strategies 3
Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview 1
Totale 7.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.947
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.947
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020711 0 0 0 0 91 122 117 96 106 68 90 21
2020/2021728 145 62 53 12 55 24 14 61 90 63 50 99
2021/20221.037 41 91 53 39 137 166 55 46 34 34 45 296
2022/20231.532 162 207 127 146 151 190 14 97 324 13 71 30
2023/20241.123 59 72 104 40 119 249 129 44 11 30 131 135
2024/2025550 31 111 56 203 149 0 0 0 0 0 0 0
Totale 7.926